Polypore Mushroom Mycelia as an Adjunct to COVID-19 Vaccination: A Randomized Clinical Trial

Le résumé fourni par la source

Abstract Use of fungal mycelium as a vaccination adjunct may constitute a novel antiviral strategy to address newly emerging viruses. In a randomized, double-blind, placebo-controlled clinical trial, we evaluated safety and feasibility of fungal mycelium ( Fomitopsis officinalis and Trametes versicolor, FoTv) as an adjunct to human COVID-19 vaccination, as well as its impact on vaccine side-effects and anti-SARS-CoV-2 antibodies (Abs). We evaluated safety, feasibility, vaccine side-effects (across 5 days), and anti-SARS-CoV-2 Ab levels (across 6 months). Safety metrics were similar for the FoTv (N=52) and Placebo (N=38) groups and the approach was feasible. Participants with detectable Abs (from prior COVID antigen exposure) were classified as “COVID-Exposed” and those with undetectable Abs as “COVID-Naive.” FoTv, versus Placebo, significantly reduced side-effects in COVID-Naive, but not in COVID-Exposed individuals. In the COVID-Naive FoTv group, Ab responses were preserved across 6 months, an effect not observed among other groups. Adjunctive FoTv was safe, feasible, and reduced vaccine side-effects without compromising (and possibly increasing) Ab levels up to 6 months in participants without previous SARS-CoV-2 exposure. Use of fungal mycelia was successfully tested as an approach to prevent a novel pandemic virus (SARS-CoV-2), with potential application to H5N1/Bird Flu and other emerging viruses.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.